文献速递介入腹部DSA

经动脉化疗栓塞治疗极早期和早期肝细胞癌:单中心经验

Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experience.
PubMed 文献 · Clin Radiol · 2022-10-22

技术成功率为98.3%,完全缓解率为45.9%,中位总生存期为71.1个月,中位无复发生存期为58.9个月,严重不良事件发生率0.8%,无30天死亡。结论认为DEB-TACE对于不适合热消融或手术的极早期和早期HCC患者安全有效,可作为移植桥接。

要点

  • TACE技术成功率高(98.3%),完全缓解率45.9%,中位OS达71.1个月。
  • DEB-TACE是主要方式(82.4%),严重不良事件仅0.8%,无30天死亡。
  • 27.8%患者最终接受移植,TACE可作为桥接治疗。

核心结论

  • DEB-TACE对于不适合热消融或手术的极早期和早期HCC患者安全有效,可能提供相当的生存获益,并可作为移植桥接。

研究设计与样本

  • 纳入标准:单发肿瘤≤5 cm,或2-3个肿瘤且每个≤3 cm。
  • 参考标准未明确报告。

诊断标准与关键数值

  • 复发率44%(48例),中位影像随访31.9个月(IQR 15.9-44.7)。
  • 中位总生存期71.1个月(95%CI 62.9-79.3),中位无复发生存期58.9个月(95%CI 47.1-70.7)。
  • 不良事件:轻度2.9%,中度5.4%,重度0.8%;无30天死亡。

临床应用与阅片要点

  • 对于不适合热消融或手术的极早期和早期HCC患者,DEB-TACE可作为有效治疗选择。
  • TACE可作为桥接移植的手段,27.8%患者最终接受移植。
  • 需注意定期影像随访监测复发,中位随访31.9个月时复发率44%。

局限性

  • 回顾性单中心设计,可能存在选择偏倚。
  • 未报告参考标准细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate the safety and efficacy of transarterial chemoembolisation (TACE) in patients with very early and early stage hepatocellular carcinoma (VES-HCC).

MATERIALS AND METHODS: A retrospective analysis was performed for all TACE procedures done at King's College Hospital, a tertiary liver centre, for VES-HCC during a 5-year period (January 2014-December 2018). Patients with solitary tumours ≤5 cm and patients with 2-3 tumours (each ≤3 cm) were included.

RESULTS: Two hundred and thirty-seven eligible patients were included. Technical success was achieved in 233 (98.3%) procedures. TACE using drug-eluting beads (DEB-TACE) was performed in 192 (82.4%) procedures. A complete response was achieved in 109 (45.9%) patients. The recurrence rate was 44% (48 cases), during a median imaging follow-up of 31.9 months (IQR 15.9-44.7). Median overall survival was 71.1 months (95% confidence interval [CI]: 62.9-79.3). Median recurrence-free survival was 58.9 months (95% CI: 47.1-70.7). Sixty-six (27.8%) patients eventually underwent transplantation, and six (2.5%) patients underwent surgical resection. Mild, moderate, and severe adverse events were encountered in 2.9%, 5.4%, and 0.8% of cases, respectively. No 30-day mortality was encountered.

CONCLUSION: DEB-TACE is safe and effective for treating VES-HCC patients, who are unsuitable for thermal ablation or surgery, and may offer comparable survival benefit. It can also be used as a bridge to transplantation for these patients.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Hashem, Sait, Thomas, et al. Transarterial chemoembolisation for very early and early stage hepatocellular carcinoma: single-centre experience. Clin Radiol. 2022. PMID: 36280515. doi:10.1016/j.crad.2022.09.120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。